目的探讨安徽省肾综合征出血热(hemorrhagic fever with renal syndrome,HFRS)流行特征,为该病的防治提供参考依据。方法通过中国疾病预防控制信息系统收集2019—2023年安徽省报告的HFRS病例资料,采用描述流行病学方法分析其流行特征,...目的探讨安徽省肾综合征出血热(hemorrhagic fever with renal syndrome,HFRS)流行特征,为该病的防治提供参考依据。方法通过中国疾病预防控制信息系统收集2019—2023年安徽省报告的HFRS病例资料,采用描述流行病学方法分析其流行特征,运用圆形分布法分析其季节特征。选取监测点开展鼠媒监测,采用夹夜法监测鼠密度,采用直接免疫荧光方法检测汉坦病毒抗原。结果2019—2023年安徽省累计报告HFRS病例808例,死亡6例,年均发病率为0.2624/10万,病死率为0.74%。16个地市均有病例报告,发病数居前3位的市分别是宣城市(227例)、滁州市和六安市(均为69例)、阜阳市(59例)。男女性病例数性别比为3.17∶1,患者年龄分布以50~59岁最多(占27.97%),职业以农民居多(占73.89%)。2019—2023年HFRS病例发病时间存在4—6月的春夏峰(占31.31%,253/808)和11月—次年1月的秋冬峰(占42.08%,340/808)两个发病高峰;圆形分布法分析结果显示,秋冬季(主高峰)及春夏季(次高峰)发病高峰日分别为12月8日和5月14日,高峰期分别为11月1日—次年1月15日和4月4日—6月25日。2019—2023年安徽省7个鼠媒监测点共放置鼠夹93543夹·次,捕鼠总数2623只,平均鼠密度为2.80%;共检测鼠肺2147份,抗原阳性66份,平均鼠带病毒率为3.07%。结论2019—2023年安徽省HFRS发病整体呈下降趋势,但暴发隐患依然存在,且发病有显著季节性,在高峰期前应尽早落实各项防控措施,有效控制HFRS的流行。展开更多
目的:探讨房颤患者血清CCN5水平是否可以预测左房低电压面积(LVZ)的大小。方法:选取2023年6月到2024年1月于烟台毓璜顶医院就诊的窦性心律患者(对照组) 79例以及首次接受心脏射频消融术的房颤患者(房颤组)114例。收集一般资料、生化、...目的:探讨房颤患者血清CCN5水平是否可以预测左房低电压面积(LVZ)的大小。方法:选取2023年6月到2024年1月于烟台毓璜顶医院就诊的窦性心律患者(对照组) 79例以及首次接受心脏射频消融术的房颤患者(房颤组)114例。收集一般资料、生化、心电图、心脏超声等临床资料。按术中行基质电压标测所得的LVZ是否大于6%将患者分为A组(LVZ Objective: To explore whether the serum CCN5 levels associated with atrial fibrosis can predict LVZ in patients with atrial fibrillation. Methods: In this study, 79 patients with sinus rhythm (control group) and 114 patients with atrial fibrillation (atrial fibrillation group) who received radiofrequency cardiac ablation for the first time in Yantai Yuhuangding Hospital between June 2023 and January 2024 were enrolled. General data, biochemistry, electrocardiogram, cardiac ultrasound and other clinical data were collected. Left atrial stroma voltage mapping was performed in patients with atrial fibrillation and LVZ area ratio was calculated. Patients were divided into group A (LVZ < 6%) and group B (LVZ ≥ 6%) according to whether LVZ was greater than 6%. The expression level of CCN5 in peripheral blood was measured by enzyme-linked immunosorbent assay. T test was used to compare the CCN5 expression level between the control group and the atrial fibrillation group. Pearson or Spearman correlation analysis was used to explore the correlation between CCN5 and clinical data. Binary Logistic regression analysis was used to determine the risk factors affecting the LVZ, and receiver operating characteristic (ROC) analysis was down to determine the cut-off value of CCN5 to predict LVZ. Results: The level of CCN5 in patients with atrial fibrillation was lower than in control group (32.43 ± 6.15 vs. 25.46 ± 4.97, P < 0.001). For atrial fibrillation patients with LVZ < 6%, blood CCN5 expression levels were lower in patients with LVZ ≥ 6% (30.10 ± 6.75 vs. 24.75 ± 3.49, P < 0.001). In patients with atrial fibrillation, CCN5 was negatively correlated with BNP level, left atrial diameter and left atrial low-voltage area ratio (P < 0.05). Logistic regression analysis suggested that blood CCN5 level was an independent risk factor for LVZ. ROC curve showed that in patients with atrial fibrillation, the optimal blood concentration of CCN5 to predict LVZ ≥ 6% was 27.22 ng/ml, sensitivity was 0.707, specificity was 0.773, and area under the curve was 0.785 [P < 0.001, CI: (0.696, 0.873)]. Conclusion: Serum CCN5 can independently predict the proportion of left atrial low-voltage area in patients with atrial fibrillation.展开更多
文摘目的探讨安徽省肾综合征出血热(hemorrhagic fever with renal syndrome,HFRS)流行特征,为该病的防治提供参考依据。方法通过中国疾病预防控制信息系统收集2019—2023年安徽省报告的HFRS病例资料,采用描述流行病学方法分析其流行特征,运用圆形分布法分析其季节特征。选取监测点开展鼠媒监测,采用夹夜法监测鼠密度,采用直接免疫荧光方法检测汉坦病毒抗原。结果2019—2023年安徽省累计报告HFRS病例808例,死亡6例,年均发病率为0.2624/10万,病死率为0.74%。16个地市均有病例报告,发病数居前3位的市分别是宣城市(227例)、滁州市和六安市(均为69例)、阜阳市(59例)。男女性病例数性别比为3.17∶1,患者年龄分布以50~59岁最多(占27.97%),职业以农民居多(占73.89%)。2019—2023年HFRS病例发病时间存在4—6月的春夏峰(占31.31%,253/808)和11月—次年1月的秋冬峰(占42.08%,340/808)两个发病高峰;圆形分布法分析结果显示,秋冬季(主高峰)及春夏季(次高峰)发病高峰日分别为12月8日和5月14日,高峰期分别为11月1日—次年1月15日和4月4日—6月25日。2019—2023年安徽省7个鼠媒监测点共放置鼠夹93543夹·次,捕鼠总数2623只,平均鼠密度为2.80%;共检测鼠肺2147份,抗原阳性66份,平均鼠带病毒率为3.07%。结论2019—2023年安徽省HFRS发病整体呈下降趋势,但暴发隐患依然存在,且发病有显著季节性,在高峰期前应尽早落实各项防控措施,有效控制HFRS的流行。
文摘目的:探讨房颤患者血清CCN5水平是否可以预测左房低电压面积(LVZ)的大小。方法:选取2023年6月到2024年1月于烟台毓璜顶医院就诊的窦性心律患者(对照组) 79例以及首次接受心脏射频消融术的房颤患者(房颤组)114例。收集一般资料、生化、心电图、心脏超声等临床资料。按术中行基质电压标测所得的LVZ是否大于6%将患者分为A组(LVZ Objective: To explore whether the serum CCN5 levels associated with atrial fibrosis can predict LVZ in patients with atrial fibrillation. Methods: In this study, 79 patients with sinus rhythm (control group) and 114 patients with atrial fibrillation (atrial fibrillation group) who received radiofrequency cardiac ablation for the first time in Yantai Yuhuangding Hospital between June 2023 and January 2024 were enrolled. General data, biochemistry, electrocardiogram, cardiac ultrasound and other clinical data were collected. Left atrial stroma voltage mapping was performed in patients with atrial fibrillation and LVZ area ratio was calculated. Patients were divided into group A (LVZ < 6%) and group B (LVZ ≥ 6%) according to whether LVZ was greater than 6%. The expression level of CCN5 in peripheral blood was measured by enzyme-linked immunosorbent assay. T test was used to compare the CCN5 expression level between the control group and the atrial fibrillation group. Pearson or Spearman correlation analysis was used to explore the correlation between CCN5 and clinical data. Binary Logistic regression analysis was used to determine the risk factors affecting the LVZ, and receiver operating characteristic (ROC) analysis was down to determine the cut-off value of CCN5 to predict LVZ. Results: The level of CCN5 in patients with atrial fibrillation was lower than in control group (32.43 ± 6.15 vs. 25.46 ± 4.97, P < 0.001). For atrial fibrillation patients with LVZ < 6%, blood CCN5 expression levels were lower in patients with LVZ ≥ 6% (30.10 ± 6.75 vs. 24.75 ± 3.49, P < 0.001). In patients with atrial fibrillation, CCN5 was negatively correlated with BNP level, left atrial diameter and left atrial low-voltage area ratio (P < 0.05). Logistic regression analysis suggested that blood CCN5 level was an independent risk factor for LVZ. ROC curve showed that in patients with atrial fibrillation, the optimal blood concentration of CCN5 to predict LVZ ≥ 6% was 27.22 ng/ml, sensitivity was 0.707, specificity was 0.773, and area under the curve was 0.785 [P < 0.001, CI: (0.696, 0.873)]. Conclusion: Serum CCN5 can independently predict the proportion of left atrial low-voltage area in patients with atrial fibrillation.
